In 2017, Advanced Medical Solutions Group reported a 16% growth in group revenue, reaching £96.9 million, with a 12% growth at constant currency. The company's adjusted operating margin increased by 250 basis points to 26.2%, while adjusted profit before tax rose by 29% to £25.4 million. Diluted earnings per share also increased by 27% to 9.39p. Net operating cash flow pre-exceptional items decreased by 4% to £21.5 million, but net cash increased by 22% to £62.5 million. The company proposed a final dividend of 0.75p per share, making a total dividend for the year of 1.10p, up 20% from 2016. Branded revenues increased by 22% to £55.2 million, while OEM revenues grew by 10% to £41.7 million. LiquiBand® topical tissue adhesives sales increased by 35% to £26.0 million, with US revenues up 47% to £18.2 million and US market share by volume increasing to 26%. RESORBA® branded products grew by 15% to £20.8 million, and antimicrobial dressings increased by 11% to £19.4 million. The company also signed an out-licensing deal with Organogenesis for a collagen-based wound dressing containing Polyhexamethylene Biguanide (PHMB), receiving royalties of £2.5 million in 2017.Advanced Medical Solutions (AMS) has reported strong revenue growth, profit performance, and cash generation in 2017. The company's revenues increased by 16% to £96.9 million, representing a 12% growth on a constant currency basis. Adjusted profit before tax increased by 29% to £25.4 million, and profit before tax increased by 32% to £25.3 million. The strong cash generation resulted in the Group ending the year with net cash of £62.5 million. AMS has consolidated its Business Units from four to two, focusing on branded products and OEM business. The company's brands, including LiquiBand, RESORBA, and ActivHeal, have shown good progress, with LiquiBand gaining a further 2% market share in the US. AMS has also agreed on a patent out-licensing agreement with Organogenisis for a collagen-based wound dressing containing Polyhexamethylene Biguanide. The Board is proposing a final dividend of 0.75p per share, making a total dividend for the year of 1.10p per share, an increase of 20%. AMS continues to be in robust financial health and is well-positioned to increase investment in internal innovation and pursue external opportunities in line with its long-term strategy and growth objectives.Advanced Medical Solutions Group's Chief Executive, Chris Meredith, reports strong results for the company, with a 16% increase in revenue to £96.9 million and a 29% improvement in adjusted profit before tax to £25.4 million. The company's growth strategy remains focused on expanding into new geographies, increasing distribution of surgical products, and enhancing their product portfolio. The Branded Business Unit reported a 22% increase in revenue to £55.2 million, with LiquiBand® topical adhesives being the largest brand, showing a 35% increase in sales. The US market saw a 47% increase in sales to £18.2 million, and the company is now targeting new geographic markets for LiquiBand®. The RESORBA® branded products portfolio saw a 15% increase in sales to £20.8 million, while ActivHeal® sales increased by 4% to £6.3 million. The OEM business reported a 10% increase in revenue to £41.7 million. The company is actively looking for acquisitions that align with their strategy and is working to ensure compliance with new European Medical Devices Regulation. Overall, the Board remains optimistic about the company's long-term prospects and potential for further growth.